is part of the Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Polymers technology to benefit from $60 million investment in Lubrizol LifeSciences business

Polymers technology to benefit from $60 million investment in Lubrizol LifeSciences business
The investment will strengthen the excipients, polymers, drug formulation and manufacturing and medical device contract manufacturing capabilities at Lubrizol LifeSciences' global facilities.

The LifeSciences business of Lubrizol Corp. (Cleveland, OH) will reap a $60 million investment to further develop new product solutions and expand capacity and manufacturing. The investment will strengthen the excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities at Lubrizol LifeSciences' global facilities, said the company in a press release published today.

Commercial drug product manufacturing will be added at the company's Particle Sciences facility in Bethlehem, PA. Leveraging the company's knowledge in complex formulations and production, the facility will be adjacent to the existing development and clinical trial manufacturing site, offering customers a seamless flow from development through manufacturing, said the release. The new space is expected to be operational in the fourth quarter of 2017, and will accommodate both sterile and non-sterile products, highly potent compounds, and organic solvent processing.    

The company also plans to expand its global facilities for excipients, polymers and contract manufacturing, with a focus on quality and efficiency. Multiple sites will be affected, with an aim to increase in-house engineering capacity across the LifeSciences portfolio of medical and pharmaceutical applications. New investment targets design, manufacturing and sterilization technologies for the production of interventional catheters and long-term implantable devices, an area of strategic importance to the medical device segment.

Lubrizol, a Berkshire Hathaway company, has been expanding its reach into the life sciences during recent years with the acquisition in 2014 of Vesta, a contract manufacturer specializing in silicone and thermoplastic extrusion, and contract drug developer Particle Science in 2015.

“Pharmaceutical companies don’t have a lot of mechanical engineering expertise, whereas medical device OEMs are not necessarily familiar with drug-delivery technology,” Robert Miller, General Manager, Lubrizol LifeSciences, told PlasticsToday at PLASTEC West in January of this year. “Lubrizol LifeSciences is fully equipped to fill that gap.”

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish